AXSM: Alzheimer’s Agitation Approval Will Drive Future Upside Potential

Axsome Therapeutics' updated analyst price target has shifted higher, with the fair value estimate moving from $223.99 to $266.94 as analysts factor in revised assumptions for revenue growth, profitability, and future P/E, while also acknowledging a slightly higher discount rate.

Analyst Commentary

Recent Street research on Axsome Therapeutics has been active, with multiple firms revisiting their price targets, fine tuning assumptions around Auvelity, the broader pipeline, and key regulatory milestones such as the AXS-05 PDUFA date for Alzheimer's disease Agitation.

Across these reports, most target changes have been framed around how quickly products can scale, the potential size of future indications, and when the company might reach sustained cash flow positivity.

Bullish Takeaways

Bullish analysts highlight what they describe as healthy Auvelity trends and see that product as a core driver in their valuation models, particularly when they factor in direct to consumer efforts and a larger sales force.
Several reports point to the AXS-05 opportunity in Alzheimer's disease Agitation, with one firm quantifying a US$1.6b potential market. This feeds directly into higher price targets and supports expectations for a larger long term revenue base.
Some analysts emphasize what they view as growing operating leverage, even alongside sales team expansion. They see this as supporting their estimates for a path to cash flow positivity and higher fair value.
Pipeline expansion beyond the current core products is cited as a reason to ascribe more value to Axsome's late stage assets. This in turn supports using richer P/E or revenue multiples in several bullish models.

Bearish Takeaways

Bearish analysts or those trimming targets, such as in the recent US$1 cut, typically signal more conservative expectations around execution, including how fast new indications can be commercialized and how that translates into earnings.
Some commentary reflects caution around regulatory timing and outcomes, with the AXS-05 PDUFA date seen as a key swing factor that could affect both growth assumptions and the appropriate discount rate.
A few reports point to commercial risk in Alzheimer's disease treatments, including concerns related to safety warnings on competing therapies. This leads some analysts to temper adoption curves and keep target prices closer to current trading levels.
There is also attention on spending needs to support launches and pipeline work, which can weigh on near term profitability and lead more conservative analysts to use less aggressive valuation multiples even when they recognize the long term product potential.

What’s in the News

The U.S. FDA approved AUVELITY for agitation associated with dementia due to Alzheimer’s disease, making it a first in class treatment targeting NMDA and sigma 1 receptors, supported by the Phase 3 ADVANCE 1 and ACCORD 2 trials (Key Developments).
In the ADVANCE 1 study, AUVELITY showed statistically significant improvement in agitation symptoms versus placebo on the CMAI scale at Week 5, with dizziness and dyspepsia reported as the most common adverse reactions and a 1.3% discontinuation rate that matched placebo (Key Developments).
In the ACCORD 2 long term trial, patients who stayed on AUVELITY experienced a statistically significantly longer time to relapse of agitation symptoms compared with those switched to placebo, supporting the longer term use data in this indication (Key Developments).
Axsome started the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness, using a design that begins with an open label period followed by a randomized withdrawal to solriamfetol or placebo (Key Developments).
Axsome reached a settlement with Alkem Laboratories over SUNOSI patents, granting Alkem a license to sell a generic SUNOSI version in the U.S. starting in 2040 or 2040 with pediatric exclusivity, subject to regulatory review and standard conditions (Key Developments).

Valuation Changes

Fair Value: the updated Street fair value estimate has moved from $223.99 to $266.94, which analysts describe as a higher assessed upside for the stock.
Discount Rate: the discount rate has edged up from 6.98% to 7.11%, reflecting slightly higher required returns in the valuation models.
Revenue Growth: modeled long term revenue growth has risen from 48.84% to 51.76%, indicating analysts are using stronger dollar revenue assumptions in their forecasts.
Net Profit Margin: the projected profit margin has shifted from 35.58% to 37.66%, pointing to a higher assumed level of dollar earnings relative to sales over time.
Future P/E: the future P/E multiple has moved modestly lower from 20.87x to 20.40x, suggesting a slightly more conservative earnings multiple applied to projected results.

11 views

Key Takeaways

Diverse CNS product portfolio and late-stage pipeline position company to capitalize on global demand trends while reducing dependence on single products.
Strategic payer access, commercial expansion, and precision R&D enhance product adoption, accelerate launches, and support long-term margin growth.
Heavy dependence on a narrow product portfolio, high expenses, payer pressures, and fierce competition threaten revenue stability, margins, and long-term financial sustainability.

Catalysts

About Axsome Therapeutics

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.What are the underlying business or industry changes driving this perspective?

Axsome's portfolio is expanding with the launch of SYMBRAVO for migraine and ongoing robust growth of Auvelity and Sunosi, reflecting increased societal prioritization of mental health and CNS disorders, which could drive further top-line revenue growth as these long-term demand trends play out globally.
The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.
Broader payer coverage and formulary wins (e.g., Auvelity's access to 83% of covered lives, expanding SYMBRAVO coverage) are improving patient access, supporting greater product adoption, which should positively impact net sales and support operating leverage as commercial infrastructure scales.
The R&D strategy leverages advancements in neuroscience and biomarker-driven precision medicine (e.g., solriamfetol in MDD with excessive sleepiness), which could accelerate pipeline progress, reduce time to market, and drive long-term margin expansion as successful launches offset early-stage SG&A investments.
Significant ongoing investments in commercialization (sales force expansion, digital-centric launch models, expected DTC campaign for Auvelity) and a strong intellectual property position favor continued penetration in high unmet-need markets, reinforcing prospects for sustained revenue growth and future improvements in net margins.

Axsome Therapeutics Earnings and Revenue Growth

Axsome Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Axsome Therapeutics's revenue will grow by 51.8% annually over the next 3 years.
Analysts assume that profit margins will increase from -26.6% today to 37.7% in 3 years time.
Analysts expect earnings to reach $932.4 million (and earnings per share of $16.57) by about May 2029, up from -$188.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.3 billion in earnings, and the most bearish expecting $-248.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.6x on those 2029 earnings, up from -61.0x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 16.8x.
Analysts expect the number of shares outstanding to grow by 4.44% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heavy future reliance on a narrow portfolio for revenue generation-with the majority of current sales coming from Auvelity and Sunosi-means that any commercial underperformance, payer pressure, or new market entrants for these lead products could result in significant revenue and earnings volatility.
Launching and scaling new products like SYMBRAVO introduces high SG&A expenses and margin headwinds in the near-to-medium term, as observed with sharply increased selling, general, and administrative expenses; if revenue ramps more slowly than anticipated, net margins could remain negative for longer than projected.
Gross-to-net discounts for key products (in the mid-50% range for Auvelity and Sunosi, and low 80% for SYMBRAVO) signal ongoing and potentially intensifying pricing and reimbursement pressures from payers and PBMs, which could cap realized revenue and limit future margin expansion.
Competitive risks are notable across all major therapeutic areas, with emerging orexin agonists for narcolepsy, entrenched polypharmacy in migraine and CNS disorders, and rapidly evolving neuroscience assets from other biopharmas-all of which could limit Axsome's future market share, slow uptake of pipeline assets, and compress revenues.
Persistent net losses ($48 million in the latest quarter), high R&D and commercial spending, and a finite cash runway (noted cash balance of $303 million, down from $315.4 million) create longer-term liquidity and shareholder dilution risks, especially if pipeline setbacks, regulatory challenges, or slow commercial launches delay the company's path to sustained profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $266.94 for Axsome Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $328.81, and the most bearish reporting a price target of just $200.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.5 billion, earnings will come to $932.4 million, and it would be trading on a PE ratio of 20.6x, assuming you use a discount rate of 7.1%.
Given the current share price of $223.06, the analyst price target of $266.94 is 16.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Axsome Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

CNS Pipeline Advancements Will Expand Global Reach